A VISIONaerie™ approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results,... Aerie Pharmaceuticals Completes Enrollment of the Netarsudil... Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and...STOCK Quote
NASDAQ: AERI
$23.19USD
Aug 16, 4:00 PM ET
VOLUME
866,547
DAY LOW/HIGH
$23.13/$24.99
52 - WEEK LOW/HIGH
$20.72/$64.45
